Prospective, Randomized, Open-label, Single center, Case Control Study To Evaluate Impact Of Eglandin® (Alprostadil) On Incidence Of Antibody-mediated Rejection According To Length Of Use In ABO-incompatible Living Donor Liver Transplant Patient

Asan Medical Center0 个研究点目标入组 160 人开始时间: 待定最近更新: 2021年5月24日

试验速览

暂无简介。

•1. Patients who received ABO blood type incompatible living liver transplantation
•2. Those who are over 19 years of age or under 80 years of age when filling out a written consent form
•3. Those who voluntarily agreed in writing to participate in clinical trials

•1. Patients undergoing liver retransplantation
•2. Patients who have received another organ transplant or plan to receive it within one year
•3. Patients receiving transplants other than liver at the same time
•4. Patients who used biometric space before transplantation
•5. Patients with a history of malignant tumors within the last 5 years or currently (except for non-metastatic basal or plate cell carcinoma/hepatocellular carcinoma of successfully treated skin)
•6. Patients with severe systemic infection who require treatment (transplantation performed after the infection is completely eliminated or controlled is possible)
•7. Transplant recipient or donor positive for HIV
•8. Take other investigational drugs 30 days before screening (date of consent) or within 5 times half-life, whichever is longer.
•9. Patients who are pregnant, nursing, or women of childbearing age who do not use proper contraception
•10. Substance abuse patients, mentally handicapped persons, or persons who are legally unable to participate in clinical trials
•11. Patients with severe heart failure and bleeding patients who may have an increased risk due to the administration of the clinical trial drug
•12. Patients with a history of hypersensitivity to THIS DRUG and its ingredients
•13. When participation in clinical trials is inappropriate due to the judgment of other researchers

发起方